Future Appears Grim For Pfizer's Tanezumab With Ostearthritis Trial Stopped
This article was originally published in The Pink Sheet Daily
Because tanezumab is the anti-NGF farthest along in development, adverse event reports could spell trouble for the entire planned class of analgesics.
You may also be interested in...
Given serious safety questions with tanezumab, the US filing seemed like throwing a Hail Mary; two FDA advisory panels overwhelmingly rejected the proposed risk management plan.
With galcanezumab for cluster headaches and migraine and tanezumab for osteoarthritis, lower back pain and cancer pain, Lilly soon could have an up-and-running pain franchise bolstering its long-term, internal R&D strategy.
Pfizer and Lilly plan to resume Phase III testing of their nerve growth factor inhibitor after FDA lifted a partial hold on tanezumab. But J&J is also poised to run new Phase III studies with fulranumab.